# US 8,278,287 B2 · siRNA compounds for inhibiting NRF2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,287 B2
- Document ID: US8278287B2
- Status: Granted
- Kind: B2
- Application number: 12/988,307
- Filed: 2009-04-06
- Published: 2011-05-05
- Granted: 2012-10-02
- Earliest claimed: 2008-04-15
- Assignees: Quark Pharmaceuticals, Inc.
- Inventors: Elena Feinstein; Igor Mett; Hagar Kalinski
- Web page: https://patentgrep.com/patent/US8278287B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 35/00: Antineoplastic agents
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/319: linked by 2'-5' linkages, i.e. having a free 3'-position
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/332: Abasic residue
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides chemically modified siRNA compounds that target the Nrf2 gene and pharmaceutical compositions comprising same useful for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.

## Claims

### Claim 1

A double-stranded compound having the structure:
5′ (N)x—Z 3′ (antisense strand)
3′ Z′—(N′)y—Z″ 5′ (sense strand)
wherein each of N and N′ is a nucleotide which may be an unmodified or a modified ribonucleotide, or may be an unconventional nucleotide moiety;
wherein each of (N)x and (N′)y is an oligonucleotide in which each consecutive N or N′ is joined to the next N or N′ by a covalent bond;
wherein Z and Z′ may be present or absent, but if present is independently 1-5 consecutive nucleotides covalently attached at the 3′ terminus of the strand in which it is present;
wherein Z″ may be present or absent, but if present is a capping moiety covalently attached at the 5′ terminus of (N′)y;
wherein x=y=19;
wherein (N)x comprises at least five alternating unmodified and modified ribonucleotides beginning at the 3′ end of (N)x and at least nine modified ribonucleotides and unconventional nucleotide moieties in total and each remaining N is an unmodified ribonucleotide;
wherein (N′)y comprises an unconventional nucleotide moiety which is selected from the group consisting of an L-DNA mirror nucleotide and a nucleotide joined to an adjacent nucleotide by a 2′-5′ internucleotide phosphate bond in at least one of the 3′ terminal position or the 3′ penultimate position; and
wherein the sequence of (N)x is 5′ UUGUCAUCUACAAACGGGA 3′ (SEQ ID NO: 8,506) and the sequence of (N)y is 5′ UCCCGUUUGUAGAUGACAA 3′ (SEQ ID NO: 8,497).

### Claim 2 (depends on 1)

The double-stranded compound according to claim 1, wherein (N′)y comprises an L-DNA mirror nucleotide at the 3′ terminal position.

### Claim 3 (depends on 1)

The double-stranded compound according to claim 1, wherein (N′)y comprises an L-DNA mirror nucleotide at the 3′ penultimate position.

### Claim 4 (depends on 1)

The double-stranded compound according to claim 1, wherein the modified ribonucleotides in (N)x comprise 2′-O-methyl sugar modified ribonucleotides.

### Claim 5 (depends on 1)

The double-stranded compound according to claim 1, wherein the unmodified ribonucleotides are present at positions 2, 4, 6, 8, 10, 12, 14, 16 and 18 and the 2′-O-methyl sugar modified ribonucleotides are present at positions 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19.

### Claim 6 (depends on 4)

The double-stranded compound according to claim 4 wherein the unmodified ribonucleotides are present at positions 1, 3, 5, 7, 9, 10, 12, 14, 16 and 18 and the 2′-O-methyl sugar modified ribonucleotide are present at positions 2, 4, 6, 8, 11, 13, 15, 17 and 19.

### Claim 7 (depends on 1)

The double-stranded compound according to claim 1 wherein (N′)y further comprises a bicyclic nucleotide.

### Claim 8 (depends on 7)

The double-stranded compound according to claim 7 wherein the bicyclic nucleotide is a locked nucleic acid (LNA) or 2′-O, 4′-C-ethylene-bridged nucleic acid (ENA).

### Claim 9 (depends on 1)

A composition comprising a pharmaceutically acceptable carrier and a double-stranded compound according to claim 1 in an amount effective to down-regulate expression of a human nuclear factor erythroid-2 related factor 2 (Nrf2) gene.

### Claim 10 (depends on 9)

A method of treating a patient suffering from a disorder comprising administering to the patient the composition according to claim 9 in a therapeutically effective dose so as to thereby treat the patient.

### Claim 11 (depends on 10)

The method of claim 10, wherein the disorder is cancer or a proliferative disease.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer is lung cancer.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the composition is administered as naked siRNA.

### Claim 14 (depends on 13)

The method of claim 13, wherein the naked siRNA is administered via aerosol to the lung of the patient.

### Claim 15 (depends on 13)

The method of claim 13, wherein the siRNA is administered via intubation or inhalation to the lung of the patient.

### Claim 16 (depends on 10)

The method according to claim 10, further comprising administering to the patient a chemotherapy drug.

### Claim 17 (depends on 16)

The method of claim 16, wherein the chemotherapy drug is a compound comprising platinum.

### Claim 18 (depends on 2)

The double-stranded compound according to claim 2, wherein (N′)y comprises a nucleotide joined to an adjacent nucleotide by a 2′-5′ internucleotide phosphate bond at the 3′ terminal position.

### Claim 19 (depends on 2)

The double-stranded compound according to claim 2, wherein (N′)y comprises a nucleotide joined to an adjacent nucleotide by a 2′-5′ internucleotide phosphate bond at the 3′ penultimate position.

### Claim 20 (depends on 19)

The double-stranded compound according to claim 19, wherein (N′)y comprises a nucleotide joined to an adjacent nucleotide by a 2′-5′ internucleotide phosphate bond in positions 17 and 18.

### Claim 21 (depends on 1)

The double-stranded compound of claim 1, wherein one or more of the nucleotides which form the 2′-5′ phosphodiester bonds further comprises a 3′-O-methyl sugar modification.
